GSK, MedTrust Online launch clinical trials iPhone app

Share this article:
GSK, MedTrust Online launch clinical trials iPhone app
GSK, MedTrust Online launch clinical trials iPhone app

GlaxoSmithKline and physician portal MedTrust Online have launched a geolocating iPhone app that lets docs look up cancer clinical trials for their patients.

The free CancerTrials App offers a quick search menu based on 12 common cancers and more advanced features that refine searches based on age, gender, trial status and other criteria. Relevant trials can be mapped relative to the location of the device.

The app draws on MedTrust Online's proprietary databases of oncology info at Oncocentric.com. Android and Blackberry versions are in the works.

“Our community of oncologists continues to ask for information about the latest therapies in a format that fits their busy schedule,” said Dr. Leo Otake, VP of medical informatics at MedTrust, in a release. “This joint development with GSK Oncology has resulted in yet another effective electronic tool that empowers our users and brings cancer doctors closer to their patients.”

“GSK Oncology has always been interested in providing doctors and their patients with the access to the right information about the best therapies that improve patient outcomes,” said GSK Oncology VP, medicine development leader Jeffrey Bloss, MD. “We are pleased to work with MedTrust Online to bring simple yet highly effective information-based solutions to the cancer community.”

Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZeneca beefs up respiratory portfolio

AstraZeneca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.